Drug reference directory
Drug reference

Pimecrolimus

Immunosuppressant · Eczema and psoriasis

ImmunosuppressantEczema and psoriasis
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated

Mechanism

Pimecrolimus is a topical drug that affects the immune response. It is used in the management of inflammatory skin conditions like eczema and psoriasis.

Indications

Mild to moderate atopic eczemaFacial, flexural and genital psoriasis (off-label, short-term, under specialist supervision, in patients whose condition has not responded adequately to other treatments, or who are intolerant of them)

Dosing

Adult
mg/wk (maximum of 15 mg/wk). This dosage may be increased. gradually to 10-25 mg/wk if needed. Widely used regimens include. weekly intramuscular injections of 10-25 mg (maximum of 30. when the cumulative dose reaches 1-1.5 g. A baseline liver biopsy. usual oral dosage is 2-3 mg/kg/day in divided doses,

Drug interactions

12 additional unreviewed or low-confidence interactions hidden because their provenance or source detail is insufficient.

Related guidelines

Other Immunosuppressant drugs

Ask House about Pimecrolimus

Continue into a citation-backed clinical answer with the drug context already attached.

Textbook-sourced·Updated: 2026-05-10